Emtricitabine

Active ingredient: Emtricitabine

In short: Emtricitabine is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Forms & strengthsEmtricitabine Capsules, containing 200 mg of emtricitabine, are size '1' capsules with sky blue cap imprinted with "EMT" in black and white body imprinted with "200" in black.
LabelCipla USA Inc.
Label updatedAug 24, 2026

What is Emtricitabine used for?

Emtricitabine is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

⚠ Boxed warning (FDA's strongest warning)

Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who

are coinfected with HIV-1 and HBV and have discontinued e

mtricitabine.

Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue emtricitabine. If appropriate, initiation of anti-hepatitis B therapy may be warranted

.

Emtricitabine dosage

Prior to or when initiating emtricitabine, test patients for hepatitis B virus infection .

Emtricitabine is taken by mouth once daily and may be taken without regard to food .

Emtricitabine capsules: One 200 mg capsule administered once daily orally.

Emtricitabine capsules: For pediatric patients weighing more than 33 kg who can swallow an intact capsule, one 200 mg capsule administered once daily orally.

Table 1 provides dosage interval adjustment for patients with renal impairment. No dosage adjustment is necessary for patients with mild renal impairment (creatinine clearance 50–80 mL/min). The safety and effectiveness of dose adjustment recommendations in patients with moderate to severe renal impairment (creatinine clearance below 50 mL/min) have not been clinically evaluated. Therefore, clinical response to treatment and renal function should be closely monitored in these patients .

Formulation | Creatinine Clearance (mL/min)

β‰₯50 mL/min | 30–49 mL/min | 15–29 mL/min | <15 mL/min or on hemodialysis

a

Capsule (200 mg) | 200 mg every 24 hours | 200 mg every 48 hours | 200 mg every 72 hours | 200 mg every 96 hours

a. Hemodialysis Patients: If dosing on day of dialysis, give dose after dialysis.

There are insufficient data available to make dosage recommendations in pediatric patients with renal impairment.

How to take Emtricitabine β€” instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and HBV

Inform patients that severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and hepatitis B virus (HBV) who have discontinued emtricitabine. Advise patients not to discontinue emtricitabine without first informing their healthcare provider. All patients should be tested for HBV infection before or when starting emtricitabine and those who are infected with HBV need close medical follow-up for several months after stopping emtricitabine to monitor for exacerbations of hepatitis .

Immune Reconstitution Syndrome

Inform patients that in some patients with advanced HIV infection (AIDS), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight infections that may have been present with no obvious symptoms. Advise patients to inform their healthcare provider immediately of any symptoms of infection . …

Warnings & precautions

Do not take this medicine if: Emtricitabine is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the products.

All patients should be tested for the presence of chronic Hepatitis B virus (HBV) before or when initiating emtricitabine .

Severe acute exacerbations of hepatitis B (e.g., liver decompensation and liver failure) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued emtricitabine. Patients who are coinfected with HIV-1 and HBV who discontinue emtricitabine should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. If appropriate, initiation of anti-hepatitis B therapy may be warranted, especially in patients with advanced liver disease or cirrhosis, since posttreatment exacerbation of hepatitis may lead to hepatic decompensation and liver failure.

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including emtricitabine. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus , Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.

Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. …

Emtricitabine side effects

The following adverse reactions are discussed in other sections of the labeling:

Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and HBV .

Immune Reconstitution Syndrome

Lactic Acidosis/Severe Hepatomegaly with Steatosis .

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse Reactions from Clinical Trials Experience in Adults

More than 2,000 adult subjects with HIV-1 infection have been treated with emtricitabine alone or in combination with other antiretroviral agents for periods of 10 days to 200 weeks in clinical trials.

The most common adverse reactions (incidence greater than or equal to 10%, any severity) identified from any of the three large, controlled clinical trials include headache, diarrhea, nausea, fatigue, dizziness, depression, insomnia, abnormal dreams, rash, abdominal pain, asthenia, increased cough, and rhinitis.

In Trials 301A and 303, the most common adverse reactions that occurred in subjects receiving emtricitabine with other antiretroviral agents were headache, diarrhea, nausea, and rash, which were generally mild to moderate. Approximately 1% of subjects discontinued participation in the clinical trials due to these events. …

Drug interactions

The potential for drug interactions with emtricitabine has been studied in combination with AZT, indinavir, d4T, famciclovir, and tenofovir DF (TDF). There were no clinically significant drug interactions for any of these drugs. Drug interactions trials are described elsewhere in the labeling .

About this medicine

Emtricitabine USP is a synthetic nucleoside analog with activity against human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.

The chemical name of emtricitabine is 5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Emtricitabine USP is the (-) enantiomer of a thio analog of cytidine, which differs from other cytidine analogs in that it has a fluorine in the 5-position.

It has a molecular formula of C8H10FN3O3S and a molecular weight of 247.24. It has the following structural formula:

Emtricitabine USP is a white to almost white crystalline powder with a solubility of approximately 112 mg/mL in water at 25 ΒΊC. The log P for FTC is -0.43 and the pKa is 2.65.

Emtricitabine capsules are for oral administration. Each capsule contains 200 mg of emtricitabine USP and the inactive ingredients, mannitol, hypromellose, and magnesium stearate. The capsule shell contains the following inactive ingredients and dyes: FD&C blue 1, titanium dioxide, gelatin, and sodium lauryl sulfate. The capsules are printed with ink containing black iron oxide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label β€” it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a229c922-58eb-4795-9219-6cebb1779e35. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin